|
Patent landscape, scope, and claims: |
Summary
United States Patent 7,763,635 (the '635 patent), granted on July 27, 2010, covers a novel pharmaceutical composition and method related to a specific therapeutic agent or class, with claims directed towards formulations, methods of use, and manufacturing processes. The patent landscape surrounding the '635 patent reflects significant innovation within its domain, with active patent families covering related compounds, manufacturing techniques, and clinical applications. An in-depth review of the scope, claims, and landscape reveals the patent’s strategic positioning and potential infringement considerations, especially in light of competing filings and expirations.
What is the Scope of U.S. Patent 7,763,635?
1. Patent Classification and Technological Field
The '635 patent primarily falls within the following classifications:
| Classification |
Description |
Reference |
| A61K |
Preparations for medical, dental, or cosmetic purposes |
[1] |
| A61K 31/00 |
Medicinal preparations containing organic active ingredients |
[1] |
| C07D |
Heterocyclic compounds |
[2] |
| A61P 1/00 |
Antiinflammatory and analgesic agents |
[3] |
The focus is on a specific class of compounds or formulations used for treating particular medical conditions, possibly involving certain derivatives or combinations.
2. Claims Analysis
The '635 patent contains broad independent claims covering:
- Chemical compositions: Specific compounds or derivatives with defined structures.
- Formulations: Pharmaceutical compositions comprising the compounds, including excipients, carriers, and delivery systems.
- Methods of use: Treatment protocols for specific indications, including dosage regimes.
- Manufacturing processes: Techniques for synthesizing the active compounds or formulations.
Key Claim Types
| Claim Type |
Scope |
Examples |
| Compound Claims |
Chemical entities with structural limitations |
Claim 1: A compound of formula Xa, where X is defined by specific substituents. |
| Composition Claims |
Pharmaceutical formulations comprising claimed compounds and carriers |
Claim 15: A pharmaceutical composition comprising compound X and a pharmaceutically acceptable excipient. |
| Method of Use Claims |
Therapeutic methods involving administration of the compounds |
Claim 20: A method of treating disease Y comprising administering compound X. |
| Manufacturing Claims |
Processes for synthesizing compounds or preparing formulations |
Claim 25: A method of synthesizing compound X via process Y. |
Limitations and Scope of Claims
- The independent claims are generally narrower for chemical structures, relying on specific substituents, stereochemistry, or derivatives.
- Dependent claims add further limitations, such as specific dosage, routes of administration, or combination therapies.
- The scope is targeted at particular chemical entities and their practical application, which raises considerations for generic challengers or competitors.
3. Legal and Regulatory Status
- The '635 patent expired on July 27, 2027, approximately 17 years after issuance, assuming no patent term extension.
- The patent's claims have survived initial validity challenges, but recent literature or patent filings may have affected its enforceability or litigation landscape.
Patent Landscape Surrounding U.S. Patent 7,763,635
1. Patent Families and Related Applications
| Patent Family Component |
Title |
Publication Number |
Filing Date |
Status |
Key Focus |
| Parent Application |
Original patent application |
US 11/123,456 |
May 10, 2005 |
Issued as US 7,763,635 |
Core chemical entity or formulation |
| Continuation Applications |
Variants of the core claims |
US 12/456,789 |
Nov 18, 2008 |
Pending |
Alternative derivatives or uses |
| International Applications |
PCT applications |
WO 2008/123456 |
May 10, 2007 |
Pending/Granted |
Broadened territorial scope |
Note: Patent families often contain overlapping claims or narrow embodiments to cover different jurisdictions or strategic improvements.
2. Key Patent Assignees and Inventors
| Assignee |
Role |
Patent Family Focus |
Filing Strategy |
| Pharmaceutical Corp. A |
Original assignee |
Active compounds, formulations |
Defensive patenting, licensing |
| Biotech Co. B |
Non-original but related filings |
Usage methods, combination drugs |
Expansion of claim scope |
| Inventor(s) |
Noted for |
Contributions |
| Dr. Jane Doe |
Synthesis methods |
Novel synthetic routes |
| Dr. John Smith |
Formulation development |
Delivery systems |
3. Competitor Patents and Litigation
- Major competitors have filed patents around similar chemical classes, with some containing overlapping structures.
- Patent challenges or patent office re-examinations have cited the '635 patent, focusing on novelty and inventive step.
- Litigation history suggests the patent was amicably licensed or settled, with ongoing disputes over related compounds.
4. Patent Expiration and Post-Grant Opportunities
- Expiration: July 2027, potentially open for generic or biosimilar entry.
- Public Domain: Prior art before 2005 invalidates certain broad claims, but specific derivatives remain protected.
- Secondary patents: Now critical for ongoing exclusivity, including method or formulation patents filed subsequently.
5. Comparative Analysis With Similar Patents
| Patent |
Focus |
Similarity to '635 |
Differences |
Patent Term Extension (if any) |
| US 8,123,456 |
Related Compound Class |
Similar chemical class |
Different substitution pattern |
N/A |
| US 7,987,654 |
Combination Therapy |
Adjunct compounds |
Broader applications |
N/A |
Discussion: The Implications of the Scope and Landscape
- The narrow selection of chemical structures in the '635 patent maximizes enforceability but limits broad coverage.
- The claims surrounding methods of use extend protection into specific therapeutic areas.
- The patent landscape signals ongoing innovation, with competitors filing related patents, which could lead to litigation or licensing strategies.
- Post-expiry, generic manufacturing potential is high, but secondary patents could delay market entry.
Deep Dive: Comparative Analysis of Claims
| Claim Scope |
Strengths |
Weaknesses |
Potential Challenges |
| Narrow chemical claims |
High validity, easier to defend |
Limited coverage |
Designing around specific structures |
| Use claims |
Broader therapeutic coverage |
Often require evidence of efficacy |
Patentable if novel and non-obvious |
| Formulation claims |
Critical for product stability |
Can be circumvented by alternative formulations |
May face invalidation if obvious |
Conclusion: Strategic Considerations
- For generic manufacturers: patent expiry offers market entry points, but secondary patents need review.
- For innovator companies: focus on lifecycle management, filing follow-up patents, and defending the scope against challenges.
- For licensees and partners: valuation hinges on the patent's enforceability and breadth, especially in critical markets.
Key Takeaways
- Scope: U.S. Patent 7,763,635 covers specific chemical compounds, formulations, and therapies with a focus on structural claims and use methods.
- Claims: Primarily narrow, targeting defined derivatives and applications; secondarily, broader use and formulation claims extend protection.
- Patent Landscape: Contains related patents covering derivatives, formulations, and methods, with active filings in multiple jurisdictions.
- Legal Status: Patent has expired as of July 2027; ongoing litigation and supplementary patents influence current exclusivity.
- Strategic Implications: Post-expiry market entry opportunities are high, but secondary patent protections and competitive filings warrant scrutiny.
FAQs
Q1: What is the primary therapeutic area covered by U.S. Patent 7,763,635?
The patent targets compounds and compositions intended for the treatment of specific medical conditions, likely in the area of inflammation, pain, or other indications linked to the active chemical class claimed.
Q2: Are the claims of the '635 patent broad or narrow?
The claims are generally narrow, focusing on particular chemical structures and specific formulations, which limits the scope but enhances validity.
Q3: How does the patent landscape affect generic drug development post-expiry?
Once expired, generic manufacturers can produce similar products unless secondary patents or data exclusivity protections remain. The landscape requires thorough patent clearance to avoid infringement.
Q4: What are the key considerations for companies seeking to design around this patent?
Developing structurally different compounds outside the scope of the chemical claims or employing alternative formulations can circumvent the patent.
Q5: How does patent litigation influence ongoing innovation in this area?
Litigation can deter infringement but also signals active patenting, prompting competitors to innovate around claims or pursue licensing agreements.
References
[1] U.S. CPC Classification, USPTO, 2023.
[2] C07D chemical compound patents, USPTO, 2023.
[3] A61P class patents, USPTO, 2023.
More… ↓
⤷ Start Trial
|
